We showed that this protocol was effective both in inducing CD8+ CTL able to lyse CLL cells in vitro (Figure 2), and in decreasing the tumor burden in vivo in the spleen and marrow of mice injected with CLL cells [15]. This evidence concerns the gene CD8A and neoplasm.